ACC.24 - Javed Butler shares the findings of the EMPACT-MI trial, in which empagliflozin had no effect on the primary endpoint in patients with acute MI but significant effect on HF hospitalizations.
No effect on the primary endpoint with SGLT2i post-MI, but significant effect on HF hospitalizations
Facebook Comments